|
Goal and Objectives:
Go To top
|
This report provides recommendations on use of the licensed quadrivalent vaccine against human papillomavirus (HPV) for HPV types 6, 11, 16, and 18 for the prevention of HPV-associated conditions such as cervical cancer, cervical cancer precursors, and anogenital warts. The recommendations were developed by CDC’s Advisory Committee on Immunization Practices. The goal of this report is to provide recommendations on the quadrivalent HPV
vaccine for clinicians, public health officials, and others who are interested in preventing HPV-associated conditions in the United States. Upon completion of this educational activity, the reader should be able to 1) describe the epidemiology of HPV in the United States, 2) identify recommendations for HPV vaccination in the United States, and 3) and describe the characteristics of quadrivalent HPV vaccine.
|